New York State Approves Quest's ColoVantage Test

The test, which was launched in late 2009, detects methylated DNA of the Septin-9 gene, which Quest licensed from Epigenomics. It is targeted at people 50 years of age and above who should be screened for colon cancer but resist.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.